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Although type 2 diabetes (T2D) is an established risk factor for hepatocellular carcinoma (HCC), the underly-
ing mechanism that connects these two diseases is unknown. Gao et al. (2013) now suggest that nuclear
receptor coactivator 5 (NCOA5) provides a genetic link between the two diseases through its effects on
hepatic IL-6 expression.Diabetes, obesity, and male gender are
associated with elevated HCC risk
(El-Serag and Rudolph, 2007; Naugler
et al., 2007). Given the increasing preva-
lence of obesity and T2D, it is important
to understand the underlyingmechanisms
linking them to HCC development.
Although previous work had implicated
inflammation in the pathogenesis of both
T2D and HCC (Donath and Shoelson,
2011; He and Karin, 2011), the precise
molecular link between the two remains
unknown. Proinflammatory cytokines
such as TNF and IL-6 are involved in
both HCC and T2D. But whereas the
tumor promoting role of IL-6 in HCC is
quite clear (Heet al., 2013), its involvement
in the pathogenesis of T2D depends on
whether it is produced acutely or chroni-
cally. Nonetheless, as far as the liver is
concerned, it is widely accepted that
chronically elevated IL-6 promotes he-
patic insulin resistance. Now the question
arises: does IL-6 link T2D to HCC? A
recent study (Gao et al., 2013) provides
some support to this hypothesis
by showing that haploinsufficiency of
NCOA5, a transcriptional regulator that
suppresses IL-6 expression, predisposes
mice to insulin resistance, T2D, and HCC.
NCOA5, also known as coactivator
independent of AF2 (CIA), is a coregulator
of estrogen receptor a (ERa)-mediated
transcription, which influences both HCC
and T2D (Naugler et al., 2007; Tiano
et al., 2011). Moreover, NCOA5 was
recently identified as a T2D susceptibility
gene (Lewis et al., 2010). In the new study,
Ncoa5+/ (haploinsufficient) male mice
were generated in two different genetic6 Cell Metabolism 19, January 7, 2014 ª2014backgrounds (due to fertility issues,
homozygous Ncoa5/ mice were not
studied) and found to develop HCC by
18 months of age. Additionally, Ncoa5+/
male mice became insulin resistant at a
young age and presented with elevated
fasting blood glucose compared to wild-
type (WT) counterparts. Insulin signaling
analysis showed that insulin-induced
phosphorylation of insulin receptor (IR-b),
insulin receptor substrate-1 (IRS-1), and
AKT is impaired in Ncoa5+/ male liver
(Figure 1). Ncoa5+/ mice also failed to
undergo a compensatory increase in b
cell mass and insulin secretion, suggest-
ing this process is also impaired. Older
(6–10 months) Ncoa5+/ males showed
liver inflammation, steatosis, fibrosis,
and dysplasia. Serum alanine amino-
transferase, a-fetoprotein, and hepatic
triglycerides were elevated relative to
WT mice. Moreover, the Ncoa5+/ liver
exhibited more cell death and compensa-
tory proliferation, a key driver of hepato-
carcinogenesis (Maeda et al., 2005).
Hepatic IL-6 and TNF were elevated,
too, mostly due to increased production
by liver myeloid cells. Although NCOA5
directly regulates IL-6 gene transcription,
other hepatocyte-specific targets for
NCOA5 that are involved in HCC develop-
ment cannot be ruled out, and future
studies should include cell type-specific
Ncoa5 gene disruption. The authors also
demonstrated an effect of NCAO5 on
IL-6 gene expression in a human macro-
phage cell line, confirming that this path-
way is not species specific. Increased
IL-6 expression in Ncoa5+/ mouse liver
resulted in activation of STAT3 andElsevier Inc.SOCS3, which negatively modulate insu-
lin signaling. The current study suggests
that chronic activation of IL-6-STAT3
signaling promotes insulin resistance in
Ncoa5+/ mice (Figure 1).
HowdoesNCOA5 regulate IL-6 expres-
sion?NCOA5 is a coactivator for ERa, and
activated ERa interferes with NF-kB-
mediated IL-6 gene transcription (Naugler
et al., 2007). Quantitative chromatin
immunoprecipitation (qChIP) in mouse
macrophage cells indicated increased
NCOA5 and ERa recruitment to the IL-6
promoter upon estrogen stimulation, and
a reporter gene assay showed that
NCOA5 represses LPS-induced NF-
kB-mediated IL-6 promoter activity.
Correspondingly, qChIP demonstrated
increased RNA Pol II recruitment to the
IL-6 promoter in Ncoa5+/ livers. There-
fore, NCOA5 haploinsufficiency increases
IL-6 gene transcription by interfering with
ERa-mediated repression.
To validate whether increased IL-6
expression is the main trigger for the
pathologies observed in Ncoa5+/ mice,
the authors generated Ncoa5+/Il-6+/
mice, which express 50% less IL-6 than
Ncoa5+/Il-6+/+ mice. Reduced IL-6
expression significantly improved fasting
blood glucose and insulin resistance.
Heterozygous IL-6 deletion, however,
was unable to block HCC development,
but it did reduce tumor load. These find-
ings are consistent with previous obser-
vations that ERa activation attenuates
chemically induced HCC development
(Naugler et al., 2007) and that IL-6 abla-
tion blocks HCC development (He et al.,
2013).
Figure 1. NCOA5 Haploinsufficiency Promotes Hepatic Inflammation, Insulin Resistance,
and HCC Development
Reduced NCOA5 expression induces insulin resistance by interfering with insulin signaling in the liver as
well as by interfering with insulin production by pancreatic b cells. NCOA5 haploinsufficiency creates a
protumorigenic microenvironment in the liver that results in HCC development, which partly depends
on IL-6 overexpression by Kupffer cells. NCOA5 is also involved in ERa-mediated suppression of IL-6.
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the different pathologies exhibited by
Ncoa5+/ mice, Gao et al. investigated
whether other factors are also involved.
They found that androgen receptor (AR),
fatty acid synthase (FAS), and TGF-b
are negatively regulated by NCOA5
(Figure 1). Therefore, in Ncoa5+/ mice,
these factors are overexpressed and
may contribute to the pathogenesis of
T2D and HCC. Previous studies have
shown that both AR (Naugler et al.,
2007) and TGF-b (Yang et al., 2013) sig-
nals contribute to HCC development.
Lastly, Gao et al. analyzed human HCC
and found that NCOA5 expression was
significantly reduced in 40% of tumors
compared to the adjacent nontumor
area. In general, when compared to a
normal liver, there is a trend of reduced
NCOA5 expression even in the nontumor
area (63%) of HCC-bearing livers. Inter-
estingly, sequencing studies revealed an
alternatively spliced isoform of NCOA5mRNA, encoding a truncated protein
that lacks the transcriptional activation
domain, s-NCOA5, whose expression is
elevated in 43% of HCC samples com-
pared to the adjacent nontumor area,
indicating an inverse correlation with full-
length NCOA5 expression.
Together these results suggest NCOA5
deficiency as a possible link between T2D
and HCC. However, it is not clear whether
obesity-induced T2D has any effect on
NCOA5 expression and whether NCOA5
deficiency contributes to HCC develop-
ment in patients suffering from nonalco-
holic steatohepatitis (NASH), most of
whom are diabetic. Clearly, more studies
are needed to determine whether environ-
mental and dietary factors modulate
NCOA5 expression, thereby influencing
T2D and HCC pathogenesis. Future
studies should also address the role of
NCAO5 in pancreatic b cell function,
hepatic glucose production, as well as
its role in insulin signaling in adipocytesCell Metabolismand skeletal muscle. Additional studies
with larger cohorts of patients with T2D,
HCC, and HCC with comorbid T2D are
needed to determine whether NCOA5
mutations or reduced expression in liver
and pancreas predispose to either or
both pathologies. This study is important
because it reinforces the inflammation-
and IL-6-based link between T2D and
HCC, suggesting that modulation of ERa
signaling may be used for the preven-
tion and/or treatment of these common
pathologies of the modern era.ACKNOWLEDGMENTS
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